Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.

Abstract

The aim of this study was to compare more conclusively the efficacy and safety of moxifloxacin, a new respiratory fluoroquinolone antibiotic, with beta-lactam-based standard therapy, which has been reported to possess good efficacy for community-acquired pneumonia (CAP). A meta-analysis of randomised controlled trials (RCTs) identified in PubMed, the Cochrane Library and Embase was performed. Seven RCTs, involving 3903 patients, were included in the meta-analysis. Moxifloxacin monotherapy was associated with similar clinical treatment success rates [clinically evaluable population, odds ratio (OR)=1.15, 95% confidence interval (CI) 0.81-1.64; intention-to-treat population, OR=1.11, 95% CI 0.86-1.42] and similar mortality (OR=0.98, 95% CI 0.66-1.46) compared with beta-lactam-based standard therapy for CAP. Microbiological treatment success rates in the moxifloxacin group were significantly higher than in the beta-lactam-based therapy group with a statistical margin (OR=1.69, 95% CI 1.02-2.80). No difference was found regarding the incidence of adverse events and serious adverse events between moxifloxacin and beta-lactam-based standard therapy. This meta-analysis provides evidence that moxifloxacin not only can be used as effectively and safely as beta-lactam-based standard therapy for CAP but also possesses a favourable pathogen eradication rate. The once-daily dosing of moxifloxacin monotherapy may be a useful alternative for beta-lactam-based standard therapy.

• Authors: Mao Mao An, Zui Zou, Hui Shen, Ping Hui Gao, Yong Bing Cao, Yuan Ying Jiang
• Journal: International journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 36 Issue 1 Pg. 58-65 (Jul 2010) ISSN: 1872-7913 [Electronic] Netherlands
• PMID: 20400271 (Publication Type: Comparative Study, Journal Article, Meta-Analysis, Randomized Controlled Trial)
• Copyright: (c) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Chemical References

• Anti-Bacterial Agents
• Aza Compounds
• Fluoroquinolones
• Quinolines
• beta-Lactams
• Moxifloxacin

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anti-Bacterial Agents (therapeutic use)
• Aza Compounds (therapeutic use)
• Community-Acquired Infections (drug therapy)
• Fluoroquinolones
• Humans
• Middle Aged
• Moxifloxacin
• Pneumonia, Bacterial (drug therapy)
• Quinolines (therapeutic use)
• Treatment Outcome
• Young Adult
• beta-Lactams (therapeutic use)